Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All that matters.....
Positron lauded for cardiac focused PET scanner Attrius
MOUNTAIN VIEW, CA, 12 March 2010 – Based on its recent analysis of the cardiac molecular imaging systems market, Frost & Sullivan recognizes Positron Corporation with the 2010 North American Award for New Product Innovation, for its pioneering cardiac positron emission tomography (PET) scanner, Attrius™. The Attrius™ was developed and optimized for molecular imaging of the heart, making it the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology.
The nuclear cardiology imaging scene has been dominated by single photon emission tomography (SPECT) until recently when the imaging world was flipped upside down by the announcement of SPECT reimbursement cuts by the Centers for Medicare and Medicaid Services (CMS), combined with the world shortage of the molybdenum-99 isotope. Many in the industry are looking for new technologies to improve their diagnostic accuracy, improve patient outcomes, reduce patient radiation exposure all while adding to their bottom line. The elusive solution to this dire situation may lie in an already well established, underutilized imaging modality: PET.
While PET is a more costly procedure than the SPECT imaging, the use of PET in cardiac nuclear medicine has been shown to reduce long-term costs and resolve clinically complicated cases.. The accuracy of PET helps reduce the need for unnecessary angiograms. It can also reduce bypass surgeries by more accurately risk stratifying patients that may require the invasive procedure from those that might benefit from alternative therapies. This modality has also been shown to quantitatively monitor therapy, which helps provide personalized medicine plan for each patient. PET, specifically without a CT, has shown to have the lowest radiation exposure for the assessment of coronary disease.
"Positron's Attrius is the only dedicated PET available today for the thousands of cardiologists and hospitals looking for a solution to today's imaging challenges," concludes Prasanna Kannan. "Implementing a PET program will allow cardiologists and hospitals to improve their diagnostic accuracy, reduce unnecessary downstream procedures, reduce patient radiation exposure, and practice more efficiency while improving their bottom line."
Taking advantage of these trends, Positron strategically introduced the industry's first cardiac optimized PET scanner. Positron’s Attrius scanner is designed to provide a significantly lower cost of ownership as compared to PET/CT modalities and does not need additional space for electronics. It has a much smaller footprint, fewer boards, easier access to the detector modules, less power consumption, and automated tuning features imbibed within it. The product can easily integrate into practices of all sizes. The table limit was increased to 450lbs, permitting larger patients to be imaged. The table is also capable of loading patients from the front or back, improving the position options for imaging.
Further, Positron’s cardiac PET scanner is one of the highest 2D sensitivity systems on the market today. It features more uniformity achieved in its slice sensitivity, consistency in the quantitation from slice-to-slice, and the ability to more accurately define the locale of a lesion or perfusion defect. The system is designed to provide concurrent acquisition, reconstruction, image processing and display, as well as, other functions such as data archiving, without interference. The Attrius™ includes many key features in its design: uniform spatial resolution in all three planes; true dynamic and gated 82Rb acquisition capability; and a unique staggered detector design for optimal quantitative results.
The Attrius™ also includes a robust, cardiac specific, imaging software package designed to ensure effortless interpretation for today’s most challenging clinical cases for nuclear cardiologists who value high quality PET imagery at an affordable price. Additional features include heart disease specific software including the ability to monitor therapy, coronary artery overlay display, open architecture for new protocol development and customization and motion correction software.
"With the introduction of Positron’s Attrius cardiac PET scanner, the issues surrounding sensitivity of PET imaging like size of detector, distance from patient, detector encoding scheme, parallelism of the electronics, and packing fraction are greatly reduced," says Frost & Sullivan Research Analyst Prasanna Kannan. "The Positron Attrius scanner's design is optimized for cardiac imaging with a large list mode memory buffer allowing for concurrent flow, perfusion and dynamic function imaging. It does not need the use of CT unlike other expensive PET/CT market offerings."
For these achievements, Positron is the worthy recipient of the 2010 Frost & Sullivan Award for New Product Innovation in the cardiac molecular imaging systems market. Each year, Frost & Sullivan presents this award to the company that has demonstrated superior performance against key competitors based on the following benchmarking criteria: innovative element of the product; leverage of leading edge technologies; value added features/benefits; increased customer value; and customer acquisition/penetration potential.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Positron Corporation
Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Besides the Attrius™, Positron products include the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron founded in 1983 and is headquartered in Indianapolis, Indiana.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
I wonder is BioMed will pick this one soon. Huge volume spike today...........maybe developments soon?
This has the vibe of a huge 2010 winner. The products are verifiable and real. The Board of Directors seals the deal here. The return of ken to the board paves the way for a huge deal.. I cannot fathom any other reason he would return. 3-5 bagger...that is a joke...that will happen in a single day soon.
Nothing is a no brainer here. That has been proven time and time again........
10k sucked as they took a big loss and backtracked on the Columbia U PR. It really means nothing though.............if they cut a big deal this will fly and the injection of funds will change the company instantly.
NWBO.OB....huge move continues....
NWBO...a rocket...
Been watching for a few months. Dove in this am @ .11.....chart looks ready IMO.
RPC- Did something new happen or was this simply a BIOMEDREPORT pump article to coincide with the frontloading and dump to follow. Seems the crafty wording fooled the novie investor...
Hopefully the films will gross a lot of money as the agencies thy've enlisted for support are not cheap. Film is an expensive business.
The price has already run up for those who got in around .04 - .05. Everyone make your own investment decisions as this was a good trade for those who entered at the mentioned levels.....even if there are a few who continue with the sub penny chant. If that happens fine....but I can tell you that is not a definite either. Those same folks also thought the trial would be good.
This one feels like a big boom is coming soon.....love where this is sitting.........crazy good opportunity....
Well greed cuts both ways.....waiting for a penny didn't turn out so well here? Never try to outsmart the market...
Glad I jumped in at .048 last week and ignored the bitter team calling for a penny or less. Goes to show you that anger can blind you from making good decisions. Burned once and burned again.
I would feel better knowing the expense side and not only projected top line revenues. There are many a film that have done good box office but were not bottom line winners. Way too much daily selling out of both etrade and fidelity to get a comfort here.....in fact it is accelerating. I expect to see more and more sellers in the short term as this looks to be a longer term play. I am interested in profit margins not projected revenues. Trading very tentatively and weak right now......will not add at this point....but hold for more clarity....a reach right now imo.
over one million
EIGH 8000 INC 1,133,125.000
After my adds today.
added 120925 shares @ .08......
Well I was enticed to cross over the million share mark on Friday. Couldn't help myself at these levels. All looks good from my end....not concerned about the daily ups and downs.....nor am I concerned about trying to lobby inpatient flippers to stay the course. While it would be nice for them to hang in and make more money.....it will likely not happen. Regardless of the credibility of a Monk, many on the pinks will not have the tolerance to hold no matter how hard you try to convince them of down the road rewards. I believe something special may evolve here with EIGH. I can only thank Monk and his Den as that is the reason this crossed my radar screen.
No worries here. Locked and loaded with a great position and we should see extraordinary gains. For me, it's best to check in periodically as I don't like a board vibe when you sense folks are trying so hard to repeatedly extoll the virtues of an investment. It's a good one and does not need repetitive reminders....that has the counter impact.........if things are developing nicely just let it happen.
Beware...BIOMED must have decided to sell the front loaded shares, thus, article releases.
I cannot access Sheffs board. Would someone please ask him why he is not following GNVC. Is there something he dislikes? Thanks
Well think I'll pack it in at the million mark. Not bad for a non-member I suppose..
EIGH 8000 INC 1,000,000.000 $0.092 $0.10 $69,308.66 $99,800.00 Pending Update ‡ Action... Buy More Sell Research News View Lots
Isn't the float locked up and it's just the effect of that which is delayed. I own almost 1 million after adds today and I'm not even a Monk member so the float must be gone....no???
Can one of you longs suggest which of the two stocks to buy? Thanks
Well I am going to give this float lock more time than I gave GRNO. Added up to almost 700k shares. This level hard to resist.
SMART TRADERS EXITED AT .0028. THIS WILL BE A SUSTAINED DESPERATE BUT FAILED PUMP IMO
GROSS REVENUES ARE MEANINGLESS AND ACTUALLY DETRIMENTAL TO FINANCIAL HEALTH IF THE COSTS ARE HIGHER THAN GROSS REVS. ANOTHER SUBTLE DETAIL TO BE AWARE OF. GROSS REVS - COSTS = PROFIT.... GROSS REVS ARE NOT PROFITS.
VINTAGE....PINK SHEETS TRICKS>>>STALLING OF ACQUISITIONS>>BUYER BEWARE
When is the idea of making 375% on your money in a week and banking it a bad idea. I think the kids college fund will appreciate the discipline to sell. Investing style is a personal choice....You talk as though there are guarantees in the market. There are no guarantees....Monk pick or not.....EIGH may very well soar...and I think if it soars that is great for the Monk crew. Maybe next lock up I hold out longer....but who knows....to each his own choices.....
That might have been the deal with the DEN but since I've not been close to those discussions on the lock up I have not way to judge the sincerity of the concept to hold for the squeeze. I would have held if more closely involved with the group but as an outsider I needed to bank the profit as the responsible thing to do. I also understand how to sell at the ask and into strength.
Listen....I own 700K shares myself. I am only saying perception will cause people to bolt or stay away when positive postings and trading volume appear to correlate to your group's presence and moral support. A 50% dip off recent highs is a trap for the novice who frequents HUB....they will panic and sell for a loss. I get the deal with the lockups only have not had the time to learn more about the DEN but I made some good cash on GRNO...in at .12 and out at .43. I don't know what the group is thinking so I had to take an almost 4 bagger..
They are nervous because of the low volume and the posts suggesting things will improve when folks return from the Monkinar. I have to say it's not comforting to think a stock your own is contigent upon a few dozen folks at a seminar. I am not suggesting that is true but that is the perception....
Looks like some bagholders left from the pump are still trying to salvage monies. Beware of this one. It was a game of shady articles with auto date update to suggest news from years ago was current.
Holding 667,400 shares here.
EIGH 8000 INC 667,400.000 $0.105 $0.112 $63,105.00 $74,748.80 Pending Update ‡ Action... Buy More Sell Research News View Lots
I had no trouble adding 70K at .114 and under. Not sure what the problem is because there is none with Fidelity.
What method do you use to establish when this will hit 30's. No one on this board can possible know although I understand the recent success have many feeling confident they are now market experts....I'm not.
Where do I add my shares....thanks
TDGI TARGET DEV GROUP INC WYO COM 1,080,867.000 $0.028 $0.029 $20,464.27 $31,561.32
This is turning out to be a top ten all time pink collapse....straight down to triples with no bottom. sad.
See the shenanigans on BIOMED disclosure long vs. none on Sheff's Board.
agree but it usually spells bagholders for many of the mindless two bit traders who dabble in pinks..